Joseph G. Jurcic, MD

Joseph G. Jurcic, MD, discusses the evolution of combination therapies in the management of myelofibrosis.

Joseph G. Jurcic, MD, discusses the use of JAK inhibitors in the management of myelofibrosis.

Although standard induction therapy produces complete remissions in 50% to 70% of patients with acute myeloid leukemia (AML), long-term survival is seen in only 20% to 40% of patients. The prognosis for older patients is even worse, with a 5-year survival rate of 5% for patients older than 65 years.